- Home
- CCEC vs CVAC Comparison
CCEC vs CVAC Comparison
Compare CCEC & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEC
- CVAC
- Stock Information
- Founded
- CCEC 2007
- CVAC 2000
- Country
- CCEC Greece
- CVAC Germany
- Employees
- CCEC N/A
- CVAC N/A
- Industry
- CCEC Marine Transportation
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- CCEC Consumer Discretionary
- CVAC Health Care
- Exchange
- CCEC Nasdaq
- CVAC Nasdaq
- Market Cap
- CCEC 1.4B
- CVAC 1.2B
- IPO Year
- CCEC 2007
- CVAC 2020
- Fundamental
- Price
- CCEC $21.59
- CVAC $5.44
- Analyst Decision
- CCEC Buy
- CVAC Hold
- Analyst Count
- CCEC 2
- CVAC 3
- Target Price
- CCEC $24.00
- CVAC $6.83
- AVG Volume (30 Days)
- CCEC 27.0K
- CVAC 687.8K
- Earning Date
- CCEC 07-31-2025
- CVAC 09-02-2025
- Dividend Yield
- CCEC 5.68%
- CVAC N/A
- EPS Growth
- CCEC 62.73
- CVAC N/A
- EPS
- CCEC 4.04
- CVAC 1.01
- Revenue
- CCEC $424,701,000.00
- CVAC $599,540,810.00
- Revenue This Year
- CCEC $19.03
- CVAC N/A
- Revenue Next Year
- CCEC $13.94
- CVAC $24.04
- P/E Ratio
- CCEC $12.52
- CVAC $5.41
- Revenue Growth
- CCEC 84.28
- CVAC 675.15
- 52 Week Low
- CCEC $14.09
- CVAC $2.37
- 52 Week High
- CCEC $24.83
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- CCEC 44.98
- CVAC 53.27
- Support Level
- CCEC $20.76
- CVAC $5.41
- Resistance Level
- CCEC $22.36
- CVAC $5.54
- Average True Range (ATR)
- CCEC 1.04
- CVAC 0.05
- MACD
- CCEC -0.09
- CVAC -0.02
- Stochastic Oscillator
- CCEC 27.13
- CVAC 23.08
About CCEC Capital Clean Energy Carriers Corp. Common Share
Capital Clean Energy Carriers Corp is an international shipping company. It is the platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.